Brief: Cyclerion Therapeutics Announces Initiation Of Patient Dosing In CY6463 Phase 2A Study In Alzheimer's Disease With Vascular Pathology

Korsana Biosciences

26/01/2022 13:52

Jan 26 (Reuters) - Cyclerion Therapeutics Inc  CYCN.O :
    * CYCLERION THERAPEUTICS ANNOUNCES INITIATION OF PATIENT
DOSING IN
CY6463 PHASE 2A STUDY IN ALZHEIMER'S DISEASE WITH VASCULAR
PATHOLOGY

Source text for Eikon:  ID:nGNX6wNc71 
Further company coverage:  CYCN.O 

 ((Reuters.Briefs@thomsonreuters.com;))